HK1009941A1 - Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers - Google Patents

Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers

Info

Publication number
HK1009941A1
HK1009941A1 HK98110893A HK98110893A HK1009941A1 HK 1009941 A1 HK1009941 A1 HK 1009941A1 HK 98110893 A HK98110893 A HK 98110893A HK 98110893 A HK98110893 A HK 98110893A HK 1009941 A1 HK1009941 A1 HK 1009941A1
Authority
HK
Hong Kong
Prior art keywords
compositions
beta
carbonic anhydrase
blockers
anhydrase inhibitors
Prior art date
Application number
HK98110893A
Other languages
English (en)
Inventor
Thomas Robert Dean
Louis Desantis
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of HK1009941A1 publication Critical patent/HK1009941A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK98110893A 1992-02-21 1998-09-24 Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers HK1009941A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83986992A 1992-02-21 1992-02-21
PCT/US1993/001487 WO1993016701A2 (en) 1992-02-21 1993-02-19 Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers

Publications (1)

Publication Number Publication Date
HK1009941A1 true HK1009941A1 (en) 1999-06-11

Family

ID=25280847

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110893A HK1009941A1 (en) 1992-02-21 1998-09-24 Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers

Country Status (10)

Country Link
EP (1) EP0625903B1 (xx)
JP (2) JP2965267B2 (xx)
AT (1) ATE169499T1 (xx)
AU (1) AU677577B2 (xx)
CA (1) CA2129037C (xx)
DE (1) DE69320329T2 (xx)
DK (1) DK0625903T3 (xx)
ES (1) ES2118941T3 (xx)
HK (1) HK1009941A1 (xx)
WO (1) WO1993016701A2 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
CA2294343A1 (en) * 1997-06-26 1999-01-07 Merck & Co., Inc. Method for optimizing retinal and optic nerve health
JP2002501017A (ja) * 1998-01-23 2002-01-15 メルク・シャープ・エンド・ドーム・ベー・ベー 視神経および網膜内の酸素圧を増加させるための方法
WO2000007584A2 (en) * 1998-08-04 2000-02-17 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
US7972612B2 (en) 2002-11-18 2011-07-05 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
US9649300B2 (en) * 2013-08-28 2017-05-16 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of WNT, TGF beta and Hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders
CA3043938A1 (en) 2016-12-21 2018-06-28 Biotheryx, Inc. Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
EP0189690B1 (en) * 1984-12-12 1989-03-01 Merck & Co. Inc. Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US4731368A (en) * 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
EP0309028A3 (en) * 1987-09-16 1990-06-27 Merck & Co. Inc. Substituted thieno(2,3-b)furan-2-sulfonamides as antiglaucoma agents
US4946859A (en) * 1989-07-31 1990-08-07 Merck & Co., Inc. 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrothieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
IE911192A1 (en) * 1990-04-12 1991-10-23 Merck & Co Inc Substituted aromatic sulfonamides as antiglaucoma agents
JP2594486B2 (ja) * 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
IL101537A (en) * 1991-04-17 1997-11-20 Merck & Co Inc OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF A CARBONIC ANHYDRASE INHIBITOR AND A b-ADRENERGIC ANTAGONIST

Also Published As

Publication number Publication date
ATE169499T1 (de) 1998-08-15
AU677577B2 (en) 1997-05-01
WO1993016701A3 (en) 1994-01-06
DE69320329D1 (de) 1998-09-17
EP0625903A1 (en) 1994-11-30
EP0625903B1 (en) 1998-08-12
DE69320329T2 (de) 1998-12-24
DK0625903T3 (da) 1999-05-10
JP2965267B2 (ja) 1999-10-18
JPH07504899A (ja) 1995-06-01
AU3725793A (en) 1993-09-13
CA2129037A1 (en) 1993-09-02
JPH10324640A (ja) 1998-12-08
CA2129037C (en) 1998-03-24
WO1993016701A2 (en) 1993-09-02
ES2118941T3 (es) 1998-10-01

Similar Documents

Publication Publication Date Title
AU1387088A (en) Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure
EP0308021A3 (en) Subsituted thieno (2,3-b)pyrole-5-sulfonamides as antiglaucoma agents
CA2129287A1 (en) Use of cloprostenol, fluprostenol and their analogues to treat glaucoma and ocular hypertension
CA2021316A1 (en) Intraocular pressure reducing 11-acyl prostaglandins
HK1009941A1 (en) Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
IE811654L (en) Ophthalmic composition
ZA979219B (en) Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum
CA2044878A1 (en) Thermally reversible and irreversible gels
PT87620A (pt) Process for preparing thiophene sulfonamide antiglaucoma agents
WO1992000287A3 (en) Analogs of carbonic anhydrase inhibitors and their use as topical iop inhibitors
BR9307099A (pt) Formulação de colírio processo para preparar uma formulação de colírio e processo de tratamento de hipertensão ocular e glaucoma
CA2247063A1 (en) Treatment of macular edema
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
KR880001290A (ko) β-차단제 및 필로카르핀-함유 제제
JPS6450886A (en) Substituted thieno(2,3-b)thiophene-2-sulfonamides as antiglaucoma
EP0366765A4 (en) Antiglaucoma compositions containing combinations of sympathomimetic agents and beta-1 selective beta-blockers
EP0309028A3 (en) Substituted thieno(2,3-b)furan-2-sulfonamides as antiglaucoma agents
EP0227416A3 (en) Dopamine agonists for treating elevated intraocular pressure
EP0527748A4 (en) Use of prostaglandin f 3 alpha as an ocular hypotensive agent
RU97116792A (ru) Способ лечения эрозий роговицы после эксимерлазерной фоторефракционной кератэктомии
RU96110996A (ru) Способ формирования доступа при операциях на перилимбальной зоне склеры
AU625096C (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20040219

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)